Before the use of extracorporeal membrane oxygenation (ECMO), infants with a severe form of congenital diaphragmatic hernia (CDH) had a high mortality and morbidity. Recent studies have shown an improvement in the survival of these infants after ECMO treatment; however, the existing data do not provide sufficient information regarding the quality of survival and developmental outcome of these infants. The objective of this study was to evaluate survival, intracranial lesions, and the neurodevelopmental outcome of infants with CDH treated with ECMO.
oxygenation index (OI) of 87 Ϯ 55 before ECMO intervention. The infants who expired (n ϭ 20) had a mean pH of 7.31 Ϯ 0.15, mean airway pressure of 23.1 Ϯ 5.5 cm H 2 O, and a mean oxygenation index of 127 Ϯ 56 before ECMO treatment. Before ECMO, survivors had a significantly lower oxygenation index and a higher PaO 2 compared with nonsurvivors (p Ͻ 0.01). A total of 18 infants (35%) had abnormal central nervous system findings. Of the 51 infants, 10 had ventricular dilatation, 6 had intracranial hemorrhage, and 11 had focal or diffuse cerebral atrophy diagnosed by computerized tomography scan or at autopsy (1 patient had an infarct). Eight infants had more than one central nervous system abnormality. A total of 16 survivors had a neurodevelopmental evaluation at 12 months, and 11 of these survivors were evaluated at 24 months of age (Bayley Scales of Infant Development). The developmental progress of these infants falls within the low-average range of cognitive and motor abilities. Their mean Bayley Mental Developmental Index was 85 Ϯ 25 (50 to 145) at 24 months; their Psychomotor Developmental Index was 89 Ϯ 21 (50 to 113) at 24 months of age. Follow-up at 4 and 6 years of age is in progress.
CONCLUSION:
Our preliminary findings indicate that 35% of infants with severe CDH requiring ECMO had central nervous system abnormalities (intracranial lesions, including ventricular dilatation). The survival rate in our study population is consistent with recent reports. As a group, infants with severe CDH display mild neuromotor and cognitive delay in development at 24 months of age.
Congenital diaphragmatic hernia (CDH) presenting with severe respiratory distress at the time of birth is associated with a high mortality. 1, 2 Histologic studies of the lungs in infants with severe CDH are consistent with pulmonary hypoplasia bilaterally. There is a decrease in the cross-sectional area of the pulmonary vascular bed, increased pulmonary arterial smooth muscle, and a decrease in the number of vessels per unit of lung. This increased pulmonary vascular resistance predisposes to right to left shunting through the patent ductus arteriosus and foramen ovale, resulting in severe hypoxia and metabolic acidosis. 3, 4 With the newer developments in perinatal ultrasound technology and awareness of the severity of illness, early detection of a diaphragmatic defect is helpful in planned delivery.
Original Article
With the availability of extracorporeal membrane oxygenation (ECMO) treatment, a significant number of infants with CDH are surviving. 5, 6 Neurodevelopmental outcome in general in ECMO survivors has been encouraging. 7, 8 However, infants with CDH represent a small proportion of the total ECMO population, and no detailed information is available about the quality of survival, intracranial lesions, and neurodevelopmental outcome in a large population of CDH infants treated with ECMO. In particular, there is no detailed information on the presence of intracranial lesions before discharge in these infants. Thus, the objective of our study was to determine the survival, intracranial abnormalities, and developmental outcome of infants with severe CDH who required ECMO treatment.
MATERIALS AND METHODS
ECMO became available at our institution in 1985 and has been used extensively in newborns with several severe forms of respiratory illness refractory to maximal conventional management. We treated 51 infants with the diagnosis of CDH at the neonatal ECMO unit at Huntington Memorial Hospital between October 1985 and February 1994, before the availability of nitric oxide at our institution. All infants were placed on ECMO after the procedure was explained to the parents and informed consent was obtained. An ECMO registry form was established for each patient, and all pertinent findings and events were entered concurrently in our neonatal database. Medical records were also reviewed for all infants. A total of 39 patients were placed on venoarterial ECMO by inserting a venous drainage cannula in the right atrium through the right internal jugular vein and an arterial perfusion cannula into the arch of the aorta through the right common carotid artery as reported previously. 5, 6 A total of 12 infants were placed on venovenous ECMO by placing a double lumen, single cannula through the internal jugular vein into the right atrium. This double lumen cannula allows for simultaneous venous drainage from the right atrium and arterial reinfusion toward the tricuspid valve. A segment of the right internal jugular vein was cannulated in all patients to drain blood from the jugular bulb into the ECMO system. With more experience, the trend has been to place more infants on venovenous ECMO.
The ECMO circuit was primed with medications and two units of donor packed red blood cells according to institutional protocol. The blood and gas flow rate in the perfusion circuit were constantly adjusted to maintain the blood gas values within standardized physiological ranges. The gas components included oxygen (21% to 100%) and carbogen (95% oxygen and 5% carbon dioxide). Pump blood flow (milliliters per minute) was estimated by multiplying the revolutions per minute of the pump head by the standard occlusion (11 ml).
Cranial and cardiac ultrasonography were performed on all patients before ECMO, and then daily while infants were on ECMO. Computerized tomography (CT) scans were performed on all infants at least once before discharge from the hospital; follow-up scans occurred if clinically indicated. The CT scans and cranial ultrasounds were read by a staff neuroradiologist. In addition, autopsies were performed on infants who expired. Because our ECMO unit is a large referral center, we were able to follow only 16 infants after discharge from our unit. The rest of the infants were transported back to their primary hospitals. The infants were followed by staff neonatologists and by personnel with specialized training in neurodevelopment (neonatal follow-up clinic). Bayley Scales were used for neurodevelopmental evaluation at 12 and 24 months. The Bayley Scales of Infant Development consist of a Mental Developmental Index and a Psychomotor Developmental Index. An average score is 100, with an SD of 16. Patients are considered "normal" if both scores are Ͼ84, "suspect" if one score is Ͻ84, and "delayed" if both scores are Ͻ84.
Proximal mean airway pressure (MAP) was measured using a ventilatory monitor (Pneumogard, Novametrix Medical Systems, Wallingford, CT) and the Infant Star Ventilator (Infrasonics, San Diego, CA). The alveolar-arterial O 2 gradient, A-a DO 2 , was derived using the simplified alveolar gas equation and the postductal PaO 2 as follows: PAO 2 ϭ 713 ϫ FIO 2 Ϫ PaCO 2 /0.8; and A-a DO 2 ϭ PAO 2 Ϫ PaO 2 , assuming a respiratory quotient of 0.8 and a barometric pressure of 760 mm Hg. The PaO 2 /PAO 2 was also calculated. In addition, the oxygenation index (OI) was calculated as follows: OI ϭ MAP ϫ FIO 2 ϫ 100/PaO 2 . The statistical significance for differences between survivors and nonsurvivors as well as differences in Bayley scores were evaluated by two-tailed Student's t-tests and Mann-Whitney rank sum tests. A p value of Ͻ0.05 was considered significant for all tests.
RESULTS

Clinical Characteristics and Survival
We retrieved data from the neonatal ECMO registry form, from the neonatal ECMO database, and from medical records in 51 infants with the diagnosis of CDH. A total of 42 infants had left-sided diaphragmatic hernia, whereas 9 infants were diagnosed with right-sided diaphragmatic hernia; of these infants, 18 were born at our hospital and 33 were referred from other hospitals. All infants had severe pulmonary hypertension diagnosed by echocardiography. Four infants who expired and six survivors had a pneumothorax before placement on ECMO. One survivor also had radiologic evidence of meconium aspiration. A total of 35 infants had hernia repair before placement on ECMO, whereas 16 infants had a delayed repair when there was no longer evidence of severe pulmonary hypertension. Other relevant clinical data are presented in Table 1 . A total of 31 infants (61%) survived, whereas 20 infants (39%) expired. Before ECMO, survivors had a significantly higher PaO 2 and a lower OI compared with nonsurvivors ( p Ͻ 0.01). Survivors also required a lower MAP compared with nonsurvivors ( p Ͻ 0.05, Table 2 ). A total of 16 infants expired while they were still in the hospital, and 4 additional infants expired after discharge. The causes of death are shown in Table 3 . A total of 39 infants were placed on venoarterial ECMO, whereas 12 infants were managed with venovenous ECMO. There was no difference in ventilatory support and blood gas values before ECMO or in survival rate between infants treated with venoarterial versus venovenous ECMO. The average postnatal age at initiation of ECMO was 29 Ϯ 41 hours (mean Ϯ SD) in our study population. Of clinical interest, the duration of ECMO in survivors was significantly shorter compared with nonsurvivors (99 Ϯ 43 hours versus 161 Ϯ 63 hours, p Ͻ 0.001).
Intracranial Lesions
All infants had cranial ultrasonography before ECMO to rule out intraventricular/intraparenchymal bleeding or other intracranial pathology contraindicating ECMO treatment. Four patients had mild ventricular dilatation, and two infants had a small intracranial hemorrhage (ICH) (grade I) before ECMO. A total of 18 infants (35%) had abnormal central nervous system findings (intracranial lesions) during their hospital stay, including ventricular dilatation (Table 4 ). An additional infant was found to have an absence of the corpus callosum. The observed complications included: ventricular dilatation, ICH, and diffuse or focal cerebral atrophy. Ventricular dilatation and ICH were the early findings diagnosed by ultrasonography, whereas cerebral atrophy was a late finding diagnosed by either CT scan or at autopsy. Of the 51 infants, 10 (20%) developed ventricular dilatation, 6 (12%) had ICH, and 11 (22%) had focal or diffuse cerebral atrophy (1 infant had an infarct). Eight infants developed more than one lesion (Table 4) . There were no significant differences between Bayley scores at 12 months and at 24 months of age. Two infants scored Ͻ70 on the most recent evaluation. The neurodevelopmental follow-up of these patients at 4 and 6 years of age is in progress.
Neurodevelopmental Outcome
DISCUSSION
Over the past 14 years, ECMO has been available for neonates with severe pulmonary and cardiovascular derangements. This relatively invasive technology has been successfully used in newborns with illnesses such as meconium aspiration syndrome, severe pneumonia, septic shock with myocardial dysfunction, and CDH associated with severe pulmonary hypertension, with an aggregate survival of 83.1% in a population with an estimated mortality of Ն80%. 9 Before the availability of ECMO, infants with severe CDH had a high mortality. The survival of patients with CDH who are symptomatic at birth has improved with the introduction of ECMO, prolonged medical stabilization, and delayed repair. Bohn et al., 10 presented data indicating that in postsurgery infants with CDH, mortality was nearly 100% when PaCO 2 was Ͼ40 mm Hg and ventilation index (MAP ϫ ventilatory rate) was Ͼ1000. This mortality was attributed to severe pulmonary hypoplasia. Other groups have shown a mortality of 60% to 80% in patients with CDH. 11, 12 Several investigators have reported a significant impact of ECMO on the survival of infants born with CDH. [13] [14] [15] In a single institution study, the post-ECMO survival was 69% compared with only 5% in pre-ECMO historical controls. The OI was comparable in both groups (Ͼ40). 15 The infants in our study had a severe form of CDH, with a mean OI of 127 in the nonsurviving group that was significantly higher than the OI in the surviving group (mean OI ϭ 87). These infants were also severely hypoxic before ECMO treatment. The overall survival in our study group was 61%, which is comparable with recent reports. 9, 16 Venovenous ECMO has been introduced recently, and this technique may have several advantages over venoarterial ECMO. 9, 17 In our study group, we did not see significant differences in mortality between patients who received venovenous or venoarterial ECMO; however, our current approach is to place all infants on venovenous ECMO unless there is a severe cardiovascular compromise or it is technically difficult due to small vessel size. We believe that preservation of the right common carotid artery by avoiding venoarterial bypass may decrease long-term morbidity in these infants.
Neurodevelopmental outcome and long-term follow-up have been documented in ECMO survivors, and the overall results are encouraging. Both short-term and long-term neurological complications are mostly related to the occurrence of severe ICH and/or cerebral infarction. Griffin et al. 18 reported that the absence of ICH and cerebral infarction before, during, and after ECMO has been associated with near-normal short-term outcome. In another study of 14 ECMO survivors, 71% had normal mental ability at 1 to 3 years of age. 19 Several other ECMO centers have reported that 70% to 80% of these infants have normal growth and development. 20, 21 Lott et al. 22 described neurophysiological measures in ECMO survivors and concluded that ECMO is associated with long-lasting decreased right internal carotid artery blood flow with a compensatory increased flow through the left carotid system, and there is a consistent reduction in the amplitude of right hemispheric long latency of evoked potentials. The long-term effects of these findings are not known at present. Infants with CDH comprise a very small group of infants in this relatively large population who survived after ECMO management. Furthermore, there is not sufficient information available on the quality of survival, occurrence of intracranial lesions, and developmental outcome in this exclusive population of infants with CDH. Van Meurs et al. 23 followed 18 infants with CDH who were treated with ECMO and concluded that the neurodevelopmental outcome of these infants was somewhat similar to other ECMO survivors; however, growth failure was the most striking finding. Stolar et al. 24 reported the neurocognitive outcome in 25 ECMO survivors with CDH compared with 26 infants treated with ECMO with other diagnoses (mean age at follow-up was 31 months). The authors found that the cognitive outcome for infants with CDH was significantly poorer compared with infants without CDH. We observed that infants with severe CDH treated with ECMO often have intracranial lesions diagnosed by cranial ultrasonography, by CT scans, or at autopsy. In our study population, 18 of 51 infants (35%) developed central nervous system complications (ventricular dilatation, ICH, or cerebral atrophy). Ventricular dilatation was an early finding in these infants; it is possible that some of these infants may have a higher intracranial pressure while in utero. Further studies need to be done to explore this concept.
A total of 16 surviving infants had an early neurodevelopmental evaluation. Our follow-up data are limited because several patients were transported back to their primary hospitals. As a group, our CDH patients displayed some neuromotor and cognitive delay in development in the first 24 months of age. Considering their severity of illness, they did not present with severe abnormalities. The majority were born outside of our ECMO center and at the time of arrival had severe hypoxemia and acidosis. These observations indicate that aggressive initial stabilization and management of these infants is warranted, and referral of infants with severe CDH to ECMO centers should be made before profound hypoxemia and acidemia occur. [25] [26] [27] ECMO has a greater impact on the survival of infants with CDH and severe pulmonary hypertension than any other therapeutic modality. 9, 28 Our patient population is distributed over 8 years. In recent years, newer techniques such as venovenous ECMO 29 and the use of a cephalad catheter have been developed for infants requiring ECMO treatment. High frequency oscillatory ventilation has also been used for the stabilization of infants with respiratory failure and for pulmonary hypertension. Nitric oxide has a vasodilatory effect on the pulmonary vasculature in adults and animals. Because infants with CDH present with severe pulmonary hypertension, inhalational nitric oxide has been used recently in the management of these infants. 30, 31 New-borns with CDH also have pulmonary hypoplasia; in a recent controlled trial, inhaled nitric oxide did not reduce the need for ECMO or death in infants with CDH. 31 Although all of the above modalities are useful in treating some infants with CDH, patients with severe diaphragmatic hernia will require ECMO treatment, and attention should be focused toward improvement of the long-term neurodevelopmental outcome in these infants.
